More Infos:

1173O
MAGRIT, a double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of the recMAGE-A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC):

MAGRIT phase III trial results raise questions
about the future of lung cancer vaccination

MADRID, Spain, 28 September 2014 – Experts are divided on the value of lung cancer vaccination after disappointing results from the MAGRIT phase III trial. The results and implications of the milestone trial are presented at the ESMO 2014 Congress in Madrid, Spain.

Professor Johan F. Vansteenkiste, first author of the MAGRIT trial and professor of medicine, Catholic University Leuven, Belgium, said: “The vaccine used in the MAGRIT trial may provide benefit if combined with immune checkpoint inhibitors that reverse the tumour’s ability to paralyse the immune system. New formulations of vaccines may also perform better.”

But Dr Martin Reck, chief oncology physician, Department of Thoracic Oncology, Hospital Grosshansdorf, Germany, said: “The results of the MAGRIT trial are disappointing for investigations of vaccines, particularly in non-small cell lung cancer, because there are now several big phase III trials which did not meet the primary endpoint. The concept of vaccination in lung cancer has to be questioned and checkpoint inhibition might be pursued instead.”

Adjuvant chemotherapy for operated lung cancer patients became standard of care following the IALT study in 2004. But cure rates remain low at around 45% and post operative chemotherapy is in general poorly tolerated by patients who have lung cancer surgery.

In the search for better adjuvant treatment after lung cancer surgery, the MAGRIT trial investigated MAGE-A3 cancer immunotherapy (also referred to as the MAGE-A3 vaccine). The MAGE-A3 protein is present in one-third of lung cancer tumours but not in normal cells making it a suitable target for drug treatment. The vaccine previously showed anti-cancer activity in metastatic melanoma¹ and in a small study of resected lung cancer.²

Vansteenkiste said: “The MAGE-A3 vaccine is very well tolerated. And in the earlier studies we found a predictive biomarker that identified patients who might have the biggest benefit from that type of treatment.”

In the MAGRIT trial, nearly 13,500 patients who had lung cancer were screened for the presence of the MAGE-A3 protein in their tumour sample. As expected, 4,210 patients (about one-third of the 12,820 valid samples) had the MAGE-A3 protein and were eligible for the trial. After excluding patients who did not meet other eligibility criteria, the remaining 2,272 patients were randomised 2:1 to receive either the active MAGE-A3 vaccine or placebo.

Vansteenkiste said: “It was a very large study but unfortunately the survival curves are superimposed. Adjuvant treatment with MAGE-A3 cancer immunotherapy did not increase disease free survival compared to placebo in the overall population (first co-primary endpoint) or in the patients who did not receive chemotherapy (second co-primary endpoint). Many patients in the latter group did not tolerate chemotherapy and the vaccine would have been a good alternative.”

He added: “The search for a predictive biomarker (third co-primary endpoint) was abandoned because of the lack of any beneficial treatment effect.”

Commenting on the implications of the results for patients with non-small cell lung cancer, Vansteenkiste said: “MAGRIT was the largest therapeutic trial ever done in non-small cell lung cancer. It joins the list of failures in the last 10 years to find an adjuvant treatment that improves outcome after lung cancer surgery. Other attempts include personalising chemotherapy according to predictive biomarkers and the use of targeted agents such as EGFR blockers – but these strategies have not been beneficial in large scale testing.”

Regarding the future of vaccines for lung cancer, Vansteenkiste said: “We need to go back to the bench to better understand the mechanisms of action. Lung cancer has a particular immunosuppressive environment in which factors in the tumour paralyse the immune system in close proximity to the tumour. Several lung cancer vaccination trials have shown that vaccines create effective soldiers, i.e. antibodies and immune cells that are able to kill tumour cells and have a treatment effect. But the problem occurs when they come to the battlefield, i.e. the environment of the tumour, where they are paralysed by factors in the tumour.”

He continued: “The more recent checkpoint inhibitors are the agents that can probably reverse this process and allow the vaccine to kill tumour cells when given in combination. Another promising area is the other vaccines in different phases of development for lung cancer patients. The MAGRIT trial confirms that vaccines are very well tolerated with mild side effects and no increase in immune-mediated disorders.”

Reck agreed that the MAGE-A3 vaccine was not harmful to patients but was less optimistic about the implications of the MAGRIT trial for vaccines in general. He said: “When the trial was designed we were enthusiastic because we had a target, a good drug with the immune stimulatory addition, and we felt we were acting very early in the disease. If any immunotherapeutic approach was going to work, it should have been in this setting and the results are therefore a big disappointment.”

Commenting on future research directions for patients with non-small cell lung cancer, Reck said: “Until now, two types of immunotherapy have been followed. MAGRIT is the most recent and largest trial of antigen specific immunotherapy using vaccines and in common with other trials could not show any improvement in efficacy. There are some subgroups which might benefit but I’m not sure whether we will be able to run these new trials.”

He concluded: “Antigen independent immunotherapy using checkpoint inhibitors is in contrast very encouraging and we are looking forward to seeing the first confirmation data. With regard to immunotherapies we are witnessing a change, with clinical trials in lung cancer concentrating on checkpoint inhibition.”

-END-

Notes to Editors

Notes

[1] Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ, Becker JC, Spatz A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, Keilholz U. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol. 2013 Jul 1;31(19):2413-2420. doi: 10.1200/JCO.2012.43.7111. Epub 2013 May 28.

[2] Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, Lopez-Brea M, Vanakesa T, Jassem J, Kalofonos H, Perdeus J, Bonnet R, Basko J, Janilionis R, Passlick B, Treasure T, Gillet M, Lehmann FF, Brichard VG. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol. 2013 Jul 1;31(19):2396-2403. doi: 10.1200/JCO.2012.43.7103. Epub 2013 May 28.

Related studies

1173O: MAGRIT, a double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of the recMAGE-A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC)

Disclaimer

Information contained in this press release was provided by the abstracts authors and reflects the content of the studies. It does not necessarily express ESMO's point of view.

Session info

1173O                    Sunday, September 28, 2014 – 16:00 PM – 17:30 PM  - Madrid Hall

Abstract: 1173O

MAGRIT, a double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of the recMAGE-A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC)

J.F. Vansteenkiste¹, B. Cho², T. Vanakesa³, T. De Pas⁴, M. Zielinski⁵, M.S. Kim⁶, J. Jassem⁷, M. Yoshimura⁸, J. Dahabreh⁹, H. Nakayama¹⁰, L. Havel¹¹, H. Kondo¹², T. Mitsudomi¹³, K. Zarogoulidis¹⁴, O.A. Gladkov¹⁵, B. Spiessens¹⁶, V. Brichard¹⁷, C. Debruyne¹⁶, P. Therasse¹⁸, N. Altorki^19
1Respiratory Oncology Unit (pulmonology), Univ Hospital Leuven, Leuven/BELGIUM, ²Division Of Oncology, Department Of Internal Medicine, Yonsei University, College of Medicine, Seoul/KOREA, ³Cardiothoracic Surgery Network, North Estonian Medical Center, Tallinn/ESTONIA, ⁴, Istituto Europeo di Oncologia, Milano/ITALY, ⁵Thoracic Surgery, Pulmonary Hospital Zakopane, Zakopane/POLAND, ⁶Center For Lung Cancer, National Cancer Center, Goyang/KOREA, ⁷Oncology And Radiotherapy, Medical University of Gdansk, Gdansk/POLAND, ⁸Divisions Of Thoracic Surgery, Department Of Surgery, Kobe University Graduate School of Medicine, KOBE/JAPAN, ⁹Athens Medical Center, Thoracic Surgery Department, Athens/GREECE, ¹⁰Thoracic Oncology, Kanagawa Cancer Center Hospital, Yokohama/JAPAN, ¹¹Pneumology- Budinova 2, Fakultni Nemocnice Na Bulovce, Phaha/CZECH REPUBLIC, ¹²General Thoracic Surgery, Kyorin University, School of Medicine, Tokyo/JAPAN, ¹³Department Of Thoracic Surgery, Kinki University Faculty of Medicine, Sayama/JAPAN, ¹⁴G. Papanikolaou Hospital, Pulmonary Department, Aristotle University of Thessaloniki, Thessaloniki/GREECE, ¹⁵Chemotherapy, Regional Oncology Center, Chelyabinsk/RUSSIAN FEDERATION, ¹⁶Medical Governance And Bioethics, GSK vaccines, Rixensart/BELGIUM, ¹⁷Immunotherapeutics Bu, GlaxoSmithKline Biologicals, Rixensart/BELGIUM, ¹⁸Dept. Clinical Oncology, GlaxoSmithKline Biologicals, Rixensart/BELGIUM, ¹⁹Thoracic Division, Department of Cardiothoracic Surgery, New York/UNITED STATES OF AMERICA

Aim: Adjuvant chemotherapy (ACT) is the standard of care for Stage II and IIIA NSCLC, and for high risk Stage IB NSCLC. However, the 5-year disease-free survival remains poor (35-50%) and about half of the patients will not receive ACT for various reasons. This Phase III trial investigated whether the recMAGE-A3+AS15 cancer immunotherapeutic (MAGE-A3 CI) as adjuvant therapy improved disease-free survival (DFS) in patients with resected NSCLC.

Methods: MAGRIT was a randomized, double-blind, placebo-controlled trial in patients with completely resected MAGE-A3-positive NSCLC Stages IB, II, and IIIA (TNM version 6) and who did or did not receive ACT. Patients were randomly assigned (2:1) to receive 13 intramuscular injections of MAGE-A3 CI or placebo over a 27-month (m) treatment period. The three co-primary endpoints were DFS in the overall and in the no-ACT population and DFS in patients with a potentially predictive gene signature (GS).

Results: Out of 13,849 patients screened, 4,210 patients had a MAGE-A3 positive tumour sample and 2,272 patients were randomised and treated. Overall, 52% of the patients received ACT; 47%, 36% and 17% were Stage IB, II and IIIA, respectively. Median age was 63 years and 24% of patients were females. Mean relative dose intensity was above 98% in both groups throughout the treatment period. Median follow-up at the time of final analysis was 38.8m. Median DFS was 60.5m and 57.9m respectively for MAGE-A3 CI and placebo (HR 1.024, 95% CI 0.891-1.177; p=0.7379). In patients who did not receive ACT, median DFS was 58.0m and 56.9m for MAGE-A3 CI and placebo groups, respectively (HR 0.970, 95% CI 0.797-1.179; p=0.7572). The rate of grade ≥ 3 adverse events (16%) did not differ between treatment groups.

Conclusions: Treatment of NSCLC patients with MAGE-A3 CI did not increase DFS compared to placebo in either the overall population or in patients who did not receive ACT. Due to the absence of treatment effect, a GS predictive of clinical benefit to MAGE-A3 CI could not be identified. Funding Source: GlaxoSmithKline Biologicals SA

Disclosure: J.F. Vansteenkiste: Pr Vansteenkiste received GSK fees as Primary investigator for the MAGRIT study.
B. Cho: Dr Cho received consultancy fees from Novartis and Boehringer-ingelheim.
T. De Pas: No conflicts of interest. Fee received from GSK as member of steering committee of the study.
J. Jassem: Dr Jassem received grant and personal fees for Consultancy from GSK.
M. Yoshimura: Pr Yoshimura received GSK fees as Primary investigator for the MAGRIT and PEARL study .
H. Nakayama: Dr Nakayama received GSK fees as Primary investigator for the MAGRIT and PEARL study .
T. Mitsudomi: Dr Mitsudomi received personal fees from GSK for an advisory role.
B. Spiessens: Bart Spiessens is employee of GSK and do own stock options of GSK.
V. Brichard: Dr Birchart is GSK employee and do own Stock options from GSK.
C. Debruyne: Dr Debruyne is GSK employee and do own GSK stock options.
P. Therasse: GSK employee and Stock options owner.
N. Altorki: Dr Altorki received GSK fees for trial conduct of GSK studies.
All other authors have declared no conflicts of interest.